Analysis of Blood Concentration Monitoring Results of Sodium Valproate in 856 Patients of Our Hospital from 2016 to 2018
- VernacularTitle:2016－2018年我院856例患者的丙戊酸钠血药浓度监测结果分析
- Author:
Chunhe LIU
1
;
Li DENG
1
;
Ying ZHAO
1
;
Lu TAN
2
;
Ruirui ZHU
2
;
Yunlin HUANG
3
;
Weiqing HUANG
4
;
Wenying CHEN
2
Author Information
1. Dept. of Pharmacy，the Affiliated Tianyou Hospital of Wuhan University of Science and Technology，Wuhan 430064，China
2. Dept. of Pharmacy，the Third Affiliated Hospital of Southern Medical University，Guangzhou 510631，China
3. Dept. of Emergency，Guangzhou Zengcheng Xintang H ospital，Guangzhou 511340，China
4. Dept. of Emergency，the First Affiliated Hospital of Guangzhou Medical University，Guangzhou 510000，China
- Publication Type:Journal Article
- Keywords:
Sodium valproate;
Steady-state blood concentration;
Treatment drug monitoring;
Rational drug use;
Influential
- From:
China Pharmacy
2020;31(3):344-348
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To reference for the rational use of sodium va lproate in clinic. METHODS ：By retrospective analysis，blood concentration monitoring results of sodium valproate and medical record data in 856 patients were collected from the Affiliated Tianyou Hospital of Wuhan University of Science and Technology during Jan. 2016-Dec. 2018. The dosage form of sodium valproate ，monitoring times of therapeutic drugs ，monitoring results of steady-state blood concentration of sodium valproate up to the standard ，dosage adjustment and the combination with carbamazepin ，fluconazol and carbapenem drugs were analyzed. Fisher exact test was used to analyze the factors influencing the steady-state blood concentration of sodium valproate up to the standard. RESULTS ：A total of 1 270 cases of sodium valproate were monitored in 856 patients，involving 407 males and 449 females，with age of （38.2±13.8）years and body mass of （52.3±10.0）kg. Among 1 270 cases of monitoring ，steady-state blood concentration of sodium valproate in 554 cases were in the range of 50-100 µg/mL，and 43.6％ of which reached the standard. The rate of reaching the standard in patients with multiple monitoring was higher than patients with single monitoring ；the dosage of patients with last monitoring reaching the standard was higher than that of patients with the first monitoring reaching the standard. The rate of reaching the standard in Sodium valproate sustained-release tablet group was higher than general Sodium valproate tablet group；the carbamazepin/fluconazol free group was higher than the carbamazepin combination group and fluconazol combination group；the carbapenem free group was higher than the carbapenem combination group （all P＜0.05）. CONCLUSIONS ：Clinical pharmacists should pay attention to the monitoring of sodium valproate treatment drugs ， strengthen the publicity and 3551851542@qq.com education of patients and their families ，and try to use Sodium valproate sustained-release tablets. When patients additionally receive carbapenem drugs like carbamazepin or fluconazol ， the standard level of sodium valproate will be reduced ，then the dosage of sodium valproate should be adjusted.
